close

Clinical Trials

1 2 3 227
Number of results: 4523

PDF print is not allowed for data more than 300.Please search above for fewer data.

Date Product Disease Phase Company Therapeutic area
2019-06-07 ADV7103 (tripotassium citrate monohydrate and potassium hydrogen carbonate) cystinuria 2-3 Advicenne (France) Rare diseases - Kidney diseases - Renal diseases
2019-03-24 aducanumab (BIIB037) Alzheimer's disease (AD) 1b Biogen (USA - MA) Neurodegenerative diseases
2019-03-21 aducanumab (BIIB037) Alzheimer's disease 3 Biogen (USA - MA) Neurodegenerative diseases
2019-03-21 aducanumab (BIIB037) Alzheimer's disease 3 Biogen (USA - MA) Neurodegenerative diseases
2019-03-18 lipid nanoparticle formulation for systemic delivery of mRNA Fabry disease preclinical Translate Bio (USA - MA) Rare diseases - Genetic diseases
2019-03-11 QR-421a (2'-O-(2-methoxyethyl)-modified antisense oligonucleotide targeting exon 13 in the USH2A gene) Usher syndrome 2A or non-syndromic retinitis pigmentosa (RP) caused by an exon 13 mutation of the causative USH2A gene 1-2 ProQR Therapeutics (The Netherlands) Rare diseases - Genetic diseases - Ophtalmological diseases
2019-03-11 RTX-134 phenylketonuria 1 Rubius Therapeutics (USA - MA) Rare diseases - Genetic diseases - Metabolic diseases
2019-03-11 ALN-AGT hypertension 1 Alnylam Therapeutics (USA - MA) Cardiovascular diseases
2019-03-06 givosiran (ALN-AS1) acute hepatic porphyria 3 Alnylam Therapeutics (USA - MA) Rare diseases - Metabolic diseases
2019-02-27 MYO-101 (self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter) beta-sarcoglycanopathy, also known as limb girdle muscular dystrophy (LGMD) type 2E 1-2a Myonexus Therapeutics (USA - MA) Rare diseases - Genetic diseases - Neuromuscular diseases
2019-02-27 NOX-A12 (olaptesed pegol) with radiotherapy newly diagnosed brain cancer patients who would not benefit from the current standard of care and whose tumor cannot be fully resected by surgery 1-2 Noxxon Pharma (Germany) Cancer - Oncology
2019-02-25 CTX001 Beta-thalassemia 1-2 CRISPR Therapeutics (Switzerland - UK) Vertex Pharmaceuticals (USA - MA) Rare diseases - Genetic diseases - Hematological diseases
2019-02-25 idebenone Duchenne muscular dystrophy (DMD) 3 Santhera Pharmaceuticals (Switzerland) Rare diseases - Genetic diseases - Neuromuscular diseases
2019-02-25 CTX001 severe sickle cell disease (SCD) 1-2 CRISPR Therapeutics (Switzerland - UK) Vertex Pharmaceuticals (USA - MA) Rare diseases - Genetic diseases
2019-02-25 ivosidenib (AG-120) in combination with azacitidine newly diagnosed isocitrate dehydrogenase-1 (IDH1) mutant acute myeloid leukemia (AML) patients 1-2 Agios Pharmaceuticals (USA -MA) Cancer - Oncology
2019-02-22 brincidofovir human herpesvirus 6 (HHV-6) viremia in allogeneic hematopoietic cell transplant (allo-HCT) recipients 3 Chimerix (USA - NC) Transplantation
2019-02-21 Zemdri® (plazomicin) bloodstream infections or hospital-acquired/ventilator-associated bacterial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE) 3 Achaogen (USA - CA) Infectious diseases
2019-02-15 DNL747 Alzheimer's disease 1b Denali Therapeutics (USA - CA) Neurodegenerative diseases
2019-02-15 Opdivo® (nivolumab) and bempegaldesleukin (NKTR-214) melanoma, renal cell carcinoma, non small cell lung cancer, urothelial carcinoma, triple negative breast cancer 1-2 BMS (USA - NY) Nektar Therapeutics (USA - CA) Cancer - Oncology
2019-02-15 CAR T CD44v6 acute myeloid leukemia, multiple myeloma 1-2 Molmed (Italy) Cancer - Oncology